Author: claimsbot

1. A surface coating material for forming a coated layer on a surface of a molten zinc bath member, wherein
the surface coating material consists of WC powder particles and a binder metal, wherein a blending ratio of the binder metal to the WC powder particles is 5 to 25% by mass,
wherein the binder metal constitutes an alloy structure having a single phase,
wherein the binder metal is an alloy comprising Co and one or more of Ni, Al, Si, Mo, Nb, Cr, W and Ta,
wherein the binder metal comprises one or more of 10 to 75% by mass of Ni, 23 to 35% by mass of Al, 0.2 to 6.0% by mass of Si, 0.2 to 15% by mass of Mo, 0.2 to 11% by mass of Nb, 0.2 to 8% by mass of Cr, 0.2 to 10% by mass of W, and 0.2 to 5% by mass of Ta relative to the total amount of the binder metal in addition to Co,
wherein the binder metal is provided in a form of an alloy powder containing 10 to 75% by mass of Ni relative to the total amount of the binder metal in addition to Co, and the alloy powder is mixed with WC powder and granulated to a powder having a particle diameter of 5 \u03bcm or more and 75 \u03bcm or less, and
wherein the binder alloy is a Co base alloy.
2. The surface coating material according to claim 1, wherein the binder metal has an immersion potential nobler than Co by 50 mV or more in aqueous environment or molten metal environment.
3. The surface coating material according to claim 1, wherein the coated layer is formed on a circumferential surface using the surface coating powder and has a thickness of 20 \u03bcm or more and 1200 \u03bcm or less.
4. A surface-coated molten zinc bath member comprising:
a molten zinc bath member; and
a coated layer provided on a surface of the molten zinc bath member, the coated layer being made of the surface coating material according to claim 1.
5. A method for producing a surface coating material for forming a coated layer on a surface of a molten zinc bath member comprising the steps of:
producing an alloy powder comprising one or more of 10 to 75% by mass of Ni, 23 to 35% by mass of Al, 0.2 to 6.0% by mass of Si, 0.2 to 15% by mass of Mo, 0.2 to 11% by mass of Nb, 0.2 to 8% by mass of Cr, 0.2 to 10% by mass of W, and 0.2 to 5% by mass of Ta relative to the total amount of the alloy powder in addition to Co, by an atomization method or by a method of pulverizing a quenched thin strip or an alloy in a thin-strip or mass form obtained by casting, wherein the alloy powder is a Co base alloy;
mixing the alloypowder with a WC powder to form a mixed powder, wherein a blending ratio of the alloy powder to the WC powder particles is 5 to 25% by mass; and
granulating the mixed powder to obtain the surface coating material,
wherein the surface coating material consists of the WC powder particles and the alloy powder, and
wherein the alloy powder contains 10 to 75% by mass of Ni relative to the total amount of the binder metal in addition to Co and the granulation is performed to provide the mixed powder with a particle diameter of 5 \u03bcm or more and 75 \u03bcm or less.
6. A method for producing a molten zinc bath member, comprising thermal spraying the surface of the molten zinc bath member with the surface coating material according to claim 1 to obtain a surface-coated molten zinc bath member.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A cooking system that delivers controlled and variable amounts of power to heat cookware, where the power is controllable from zero power up to a maximum power output capacity of the cooking system, comprising:
a user-manipulated heating control user interface that is adapted to be turned up and turned down by the user to a particular setting within a temperature operating range that comprises a first portion that encompasses the boiling point, a second portion that is below the first portion, and a third portion that is above the first portion; and
a controller that is input with the user interface setting and is configured to determine a command to control the heating of the cookware and output the command so as to control the power provided to the cookware;
wherein the power provided to the cookware at any given time ranges up to a maximum controlled power output; and
wherein in the first portion of the temperature operating range the maximum controlled power output is variable, is under user control via the user interlace, and is limited to be less than the maximum power output capacity of the cooking system.
2. The cooking system of claim 1 further comprising a temperature sensor that senses a temperature of the cooking utensil:
wherein the controller is further input with the sensed temperature of the cooking utensil and a particular temperature representing the boiling point; and
wherein in the first portion of the temperature operating range the controller is further configured to determine the command to control the heating of the cookware based on the sensed temperature of the cooking utensil and the particular temperature representing the boiling point, so as to maintain the cooking temperature at the particular temperature representing the boiling point.
3. The cooking system of claim 1 wherein in the first portion of the temperature operating range the maximum controlled power output increases as the user interface is turned up.
4. The cooking system of claim 1 wherein in the first portion of the temperature operating range the maximum controlled power output increases monotonically as the user interface is turned up.
5. The cooking system of claim 1 wherein over the entire first portion of the temperature operating range the maximum controlled power output increases monotonically as the user interface is turned up.
6. The cooking system of claim 1 wherein over the first portion of the temperature operating range the maximum controlled power output increases from zero power at the lowest temperature of the first portion of the temperature operating range to the maximum power output capacity of the cooking system at the highest temperature of the first portion of the temperature operating range.
7. The cooking system of claim 1 wherein in the second portion of the temperature operating range the maximum controlled power output is equal to the maximum power output capacity of the cooking system.
8. The cooking system of claim 1 wherein over the entire second portion of the temperature operating range the maximum controlled power output is equal to the maximum power output capacity of the cooking system.
9. The cooking system of claim 1 wherein in the third portion of the temperature operating range the maximum controlled power output is equal to the maximum power output capacity of the cooking system.
10. The cooking system of claim 1 wherein over the entire third portion of the temperature operating range the maximum controlled power output is equal to the maximum power output capacity of the cooking system.
11. A cooking system that delivers controlled and variable amounts of power to heat cookware, where the power is controllable from zero power up to a maximum power output capacity of the cooking system, comprising:
a user-manipulated heating control user interface that is adapted to be turned up and turned down by the user to a particular setting within a temperature operating range that comprises a first portion that encompasses the boiling point, a second portion that is below the first portion, and a third portion that is above the first portion; and
a controller that is input with the user interface setting and is configured to determine a command to control the heating of the cookware and output the command so as to control the power provided to the cookware;
wherein the power provided to the cookware at any given time ranges up to a maximum controlled power output;
wherein in the first portion of the temperature operating range the maximum controlled power output is variable, is under user control via the user interface, and increases monotonically as the user interface is turned up; and
wherein in the second and third portions of the temperature operating range the maximum controlled power output is equal to the maximum power output capacity of the cooking system.
12. The cooking system of claim 11 wherein over the entire first portion of the temperature operating range the maximum controlled power output increases monotonically as the user interface is turned up.
13. The cooking system of claim 11 wherein over the entire second and third portions of the temperature operating range the maximum controlled power output is equal to the maximum power output capacity of the cooking system.
14. The cooking system of claim 11 further comprising a temperature sensor that senses a temperature of the cooking utensil;
wherein the controller is further input with the sensed temperature of the cooking utensil and a particular temperature representing the boiling point; and
wherein in the first portion of the temperature operating range the controller is further configured to determine the command to control the heating of the cookware based on the sensed temperature of the cooking utensil and the particular temperature representing the boiling point, so as to maintain the cooking temperature at the particular temperature representing the boiling point.
15. A cooking system that delivers controlled and variable amounts of power to heat cookware, where the power is controllable from zero power up to a maximum power output capacity of the cooking system, comprising:
a user-manipulated heating control user interface that is adapted to be turned up and turned down by the user to a particular setting within a temperature operating range that comprises a first portion that encompasses the boiling point, a second portion that is below the first portion, and a third portion that is above the first portion;
a temperature sensor that senses a temperature of the cooking utensil;
a controller that is input with the user interface setting, the sensed temperature of the cooking utensil, and a particular temperature representing the boiling point, wherein the controller is configured to determine a command to control the heating of the cookware and output the command so as to control the power provided to the cookware;
wherein the power provided to the cookware at any given time ranges up to a maximum controlled power output;
wherein in the first portion of the temperature operating range the controller is further configured to determine the command to control the heating of the cookware based on the sensed temperature of the cooking utensil and the particular temperature representing the boiling point, so as to maintain the cooking temperature at the particular temperature representing the boiling point;
wherein over the entire first portion of the temperature operating range the maximum controlled power output is variable, is under user control via the user interface, and increases monotonically as the user interface is turned up from zero power at the lowest temperature of the first portion of the temperature operating range, to the maximum power output capacity of the cooking system at the highest temperature of the first portion of the temperature operating range; and
wherein over the entire second and third portions of the temperature operating range the maximum controlled power output is equal to the maximum power output capacity of the cooking system.

What is claimed is:

1. A compound selected from the group consisting of the following formulae:

17
wherein:
A is C(R8) or N (where R8 is hydrogen, alkyl or halo);
Z1 is O, N(R9), CH2O or S(O)n (where n is 0 to 2);
Z2 is O, N(R9), OCH2 or S(O)n (where n is 0 to 2);
R1 and R4 are each independently hydrogen, halo, alkyl, nitro, OR9, C(O)OR9, C(O)N(R9)R10, N(R9)R10, N(R9)C(O)R9, or N(H)S(O)2R11;
R2 is C(NH)NH2, C(NH)N(H)OR9, C(NH)N(H)C(O)OR11, C(NH)N(H)C(O)R9, C(NH)N(H)S(O)2R11, or C(NH)N(H)C(O)N(H)R9;
R3 is hydrogen, halo, alkyl, haloalkyl, nitro, ureido, guanidino, OR9, C(NH)NH2, C(NH)N(H)OR9, C(O)N(R9)R10, R12C(O)N(R9)R10, CH(OH)C(O)N(R9)R10, N(R9)R10, R12N(R9)R10, C(O)OR9, R12C(O)OR9, N(R9)C(O)R9, (1,2)-tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2)-imidazolyl (optionally substituted by alkyl), or (1,2)-imidazolinyl (optionally substituted by alkyl);
R5 and R6 are independently hydrogen, halo, alkyl, haloalkyl, nitro, N(R9)R10, C(O)OR9, C(O)N(R9)R10, C(O)N(R9)CH2C(O)N(R9)R10, N(R9)C(O)N(R9)R10 N(R9)C(O)R10, N(R9)S(O)2R11, or N(R9)C(O)N(R9)CH2C(O)N(R9)R10;
R7 is XCH2C(R13)HpC(R13)H2 or XC(C(R13)HpC(R13)H2)2H where:
p is 0 to 5;
X is O, S(O)n (where n is 0 to 2), or N(R9);

and each R13 is independently C(OR9)HmCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9, CH2nN(R9)R10, CH2nOC(O)R9, CH2nSC(O)R9, CH2nN(R9)C(O)R9, CH2nOC(O)OR11, CH2nN(R9)C(O)OR11, CH2nOC(O)N(R9)R10, or CH2nN(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);
or R7 is selected from the group consisting of the following formulae:

18
where
q is 0 to 4;
p is 0 to 5;
each R13 is independently C(OR9)HmCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9, CH2nN(R9)R10, (CH2)nOC(O)R9, CH2nSC(O) R9, CH2nN(R9)C(O)R9, CH2nOC(O)OR11, CH2nN(R9)C(O)OR11, CH2nOC(O)N(R9)R10, or CH2nN(R9)C(O)N(R9)R10 (where each n is independently 0 to 2); and
each R14 is XCH2r or XCH2C(R13)Hr, where:
each r is independently 0 to 5, and
each X is O, S(O)n (where n is 0 to 2), or N(R9); and
each R13 is independently CH(OR9)mCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9, CH2nN(R9)R10, CH2nOC(O)R9, CH2nSC(O)R9, CH2nN(R9)C(O)R9, CH2nOC(O)OR11, CH2nN(R9)C(O)OR11, CH2nOC(O)N(R9)R10, or CH2nN(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);

each R9 and R10 is independently hydrogen, alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl);
each R11 is alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl); and
each R12 is independently an alkylene or alkylidene chain;
as a single stereoisomer or a mixture thereof; or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 selected from formula (I):

19
as a single stereoisomer or a mixture thereof; or a pharmaceutically acceptable salt thereof.
3. The compound of claim 2 wherein:
A is N;
Z1 is O, CH2O or S(O)n (where n is 1);
Z2 is O, OCH2 or S(O)n (where n is 1);
R1 and R4 are each independently hydrogen, halo, alkyl or OR9;
R2 is C(NH)NH2, C(NH)N(H)S(O)2R11 or C(NH)N(H)C(O)N(H)R9;
R3 is ureido, guanidino, N(R9)R10, N(R9)C(O)R9, (1,2)-tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2)-imidazolyl (optionally substituted by alkyl) or (1,2)-imidazolinyl (optionally substituted by alkyl);
R5 and R6 are independently hydrogen, halo, alkyl or haloalkyl;
R7 is XCH2C(R13)HpC(R13)H2 where:
p is 0 to 5;
X is O, S(O)n (where n is 0 to 2), or N(R9);

and each R13 is independently C(OR9)HmCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9, CH2nN(R9)R10, CH2nOC(O)R9, CH2nSC(O)R9, CH2nN(R9)C(O)R9, CH2nOC(O)OR11, CH2nN(R9)C(O)OR11, CH2nOC(O)N(R9)R10, or CHnN(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);
each R9 and R10 is independently hydrogen, alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl); and
each R11 is alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl).
4. The compound of claim 3 wherein:
A is N;
Z1 is O;
Z2 is O;
R1 is hydrogen or OR9;
R2 is C(NH)NH2;
R3 is (1,2)-tetrahydropyrimidinyl (optionally substituted by methyl), (1,2)-imidazolyl (optionally substituted by methyl) or (1,2)-imidazolinyl (optionally substituted by methyl);
R4 is hydrogen;
R5 and R6 are each halo;
R7 is XCH2C(R13)HpC(R13)H2 where:
p is 0 to 5;
X is O;
and each R13 is independently C(OR9)HmCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9, CH2nN(R9)R10, CH2nOC(O)R9, CH2nSC(O)R9, CH2nN(R9)C(O)R9, CH2nOC(O)OR11, CH2nN(R9)C(O)OR11, CH2nOC(O)N(R9)R10, or CH2nN(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);

each R9 and R10 is independently hydrogen or alkyl; and
each R11 is alkyl or aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl).
5. The compound of claim 4 wherein:
A is N;
Z1 is O;
Z2 is O;
R1 is OR9;
R2 is C(NH)NH2;
R3 is (1,2)-imidazolyl (optionally substituted by methyl) or (1,2)-imidazolinyl (optionally substituted by methyl);
R4 is hydrogen;
R5 and R6 are both fluoro;
R7 is XCH2C(R13)HpC(R13)H2 where:
p is 0 to 5;
X is O;
and each R13 is independently C(OR9)HmCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9 or CH2nN(R9)R10 (where each n is independently 0 to 2); and

each R9 and R10 is independently hydrogen or alkyl.
6. The compound of claim 5 wherein:
R7is OCH2C(OH)HC(OH)H2.
7. The compound of claim 6, namely, 3-3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-(2,3-dihydroxypropoxy)pyridin-2-yloxy-4-hydroxybenzamidine.
8. The compound of claim 2 wherein:
A is N;
Z1 is O, CH2O or S(O)n (where n is 0 to 2);
Z2 is O, OCH2 or S(O)n (where n is 0 to 2);
R1 and R4 are each independently hydrogen, halo or OR9;
R2 is C(NH)NH2, C(NH)N(H)S(O)2R11 or C(NH)N(H)C(O)N(H)R9;
R3 is ureido, guanidino, N(R9)R10, N(R9)C(O)R9, (1,2)-tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2)-imidazolyl (optionally substituted by alkyl), or (1,2)-imidazolinyl (optionally substituted by alkyl);
R5 and R6 are independently hydrogen, halo, alkyl or haloalkyl;
R7 is selected from the group consisting of the following formulae:

20
where
q is 0 to 4;
p is 0 to 5;
each R13 is independently C(OR9)HmCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9, CH2nN(R9)R10, (CH2)nOC(O)R9, CH2nSC(O)R9, CH2nN(R9)C(O)R9, CH2nOC(O)OR11, CH2nN(R9)C(O)OR11, CH2nOC(O)N(R9)R10, or CH2nN(R9)C(O)N(R9)R10 (where each n is independently 0 to 2); and
each R14 is XCH2r or XCH2C(R13)Hr where:
each r is independently 0 to 5, and
each X is O, S(O)n (where n is 0 to 2), or N(R9); and
each R13 is independently CH(OR9)mCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9, CH2nN(R9)R10, CH2nOC(O)R9, CH2nSC(O)R9, CH2nN(R9)C(O)R9, CH2nOC(O)OR11, CH2nN(R9)C(O)OR11, CH2nOC(O)N(R9)R10, or CH2nN(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);

each R9 and R10 is independently hydrogen, alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl);
each R11 is alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl).
9. The compound of claim 8 wherein:
A is N;
Z1 is O;
Z2 is O;
R1 is hydrogen or OR9;
R2 is C(NH)NH2;
R3 is (1,2)-tetrahydropyrimidinyl (optionally substituted by methyl), (1,2)-imidazolyl (optionally substituted by methyl), or (1,2)-imidazolinyl (optionally substituted by methyl);
R4 is hydrogen;
R5 and R6 are each halo;
R7 is selected from the group consisting of the following formulae:

21
where
q is 0 to 4;
p is 0 to 5;
each R13 is independently C(OR9)HmCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9, CH2nN(R9)R10, (CH2)nOC(O)R9, CH2nSC(O)R9, CH2nN(R9)C(O)R9, CH2nOC(O)OR11, CH2nN(R9)C(O)OR11, CH2nOC(O)N(R9)R10, or CH2nN(R9)C(O)N(R9)R10 (where each n is independently 0 to 2); and
each R14 is XCH2r or XCH2C(R13)Hr, where:
each r is independently 0 to 5, and
each X is O, S(O)n (where n is 0 to 2), or N(R9); and
each R13 is independently CH(OR9)mCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9, CH2nN(R9)R10, CH2nOC(O)R9, CH2nSC(O)R9, CH2nN(R9)C(O)R9, CH2nOC(O)OR11, CH2nN(R9)C(O)OR11, CH2nOC(O)N(R9)R10, or CH2rN(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);

each R9 and R10 is independently hydrogen or alkyl; and
each R11 is independently alkyl or aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl).
10. The compound of claim 9 wherein:
A is N;
Z1 is O;
Z2 is O;
R1 is OR9;
R2 is C(NH)NH2;
R3 is (1,2)-imidazolyl (optionally substituted by methyl), or (1,2)-imidazolinyl (optionally substituted by methyl);
R4 is hydrogen;
R5 and R6 are both fluoro;
R7 is selected from the group consisting of the following formulae:

22
where
q is 0 to 4;
p is 0 to 5;
each R13 is independently C(OR9)HmCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9 or CH2nN(R9)R10 (where each n is independently 0 to 2); and
each R14 is XCH2r or XCH2C(R13)Hr, where:
each r is independently 0 to 5, and
each X is independently O, S(O)n (where n is 0 to 2), or N(R9); and
each R13 is independently CH(OR9)mCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9 or CH2nN(R9)R10; and

each R9 and R10 is independently hydrogen or alkyl.
11. The compound of claim 10 wherein R7 is:

23
where
q is 0 to 4;
each R13 is independently C(OR9)HmCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9 or CH3nN(R9)R10 (where each n is independently 0 to 2); and
each R14 is XCH2r or XCH2C(R13)Hr, where:
each r is independently 0 to 5, and
each X is independently O, S(O)n (where n is 0 to 2), or N(R9); and
each R13 is independently CH(OR9)mCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9 or CH2nN(R9)R10; and

each R9 and R10 is independently hydrogen or alkyl.
12. The compound of claim 11 wherein R7 is:

24
where
q is 0 to 4;
each R13 is independently C(OR9)HmCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9 or CH2nN(R9)R10 (where each n is independently 0 to 2); and
each R14 is XCH2r where:
r is 0 to 5, and
X is O, S(O)n (where n is 0 to 2), or N(R9); and

each R9 and R10 is independently hydrogen or alkyl.
13. The compound of claim 12 wherein R7 is:

25
where
q is 0 to 4;
each R13 is independently C(OR9)HmCH2OR9 (where m is 1 to 4), CH2nOR9 or CH2nN(R9)R10 (where each n is independently 0 to 2); and
each R14 is XCH2r where:
r is 0 or 1, and
X is O; and

each R9 and R10 is independently hydrogen or alkyl.
14. The compound of claim 13 wherein R7 is:

26
where R14 is O; q is 3 and one R13 is in the 4-position of the tetrahydrofuranyl ring and is hydroxy, the second R13 is in the 2-position of the tetrahydrofuranyl ring and is 2,3-dihydroxyethyl and the third R13 is in the 5-position of the tetrahydrofuranyl ring and is ethoxy.
15. The compound of claim 14, namely, 3-3,5-difluoro-6-(3 (1-methylimidazolin-2-yl)phenoxy)-4-2-(1,2-dihydoxyethyl)-4-hydroxy-5-ethoxytetrahydrofuran-3-yloxypyridin-2-yloxy-4-hydroxybenzamidine.
16. A pharmaceutical composition useful in treating a human having a disease-state characterized by thrombotic activity, which composition comprises a therapeutically effective amount of a compound selected from the group consisting of the following formulae:

27
wherein:
A is C(R8) or N (where R8 is hydrogen, alkyl or halo);
Z1 is O, N(R9), CH2O or S(O)n (where n is 0 to 2);
Z2 is O, N(R9), OCH2 or S(O)n (where n is 0 to 2);
R1 and R4 are each independently hydrogen, halo, alkyl, nitro, OR9, C(O)OR9, C(O)N(R9)R10, N(R9)R10, N(R9)C(O)R9, or N(H)S(O)2R11;
R2 is C(NH)NH2, C(NH)N(H)OR9, C(NH)N(H)C(O)OR11, C(NH)N(H)C(O)R9, C(NH)N(H)S(O)2R11, or C(NH)N(H)C(O)N(H)R9;
R3 is hydrogen, halo, alkyl, haloalkyl, nitro, ureido, guanidino, OR9, C(NH)NH2, C(NH)N(H)OR9, C(O)N(R9)R10, R12C(O)N(R9)R10, CH(OH)C(O)N(R9)R10, N(R9)R10, R12N(R9)R10, C(O)OR9, R12C(O)OR9, N(R9)C(O)R9, (1,2)-tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2)-imidazolyl (optionally substituted by alkyl), or (1,2)-imidazolinyl (optionally substituted by alkyl);
R5 and R3 are independently hydrogen, halo, alkyl, haloalkyl, nitro, N(R9)R10, C(O)OR9, C(O)N(R9)R10, C(O)N(R9)CH2C(O)N(R9)R10, N(R9)C(O)N(R9)R10, N(R9)C(O)R10, N(R9)S(O)2R11, or N(R9)C(O)N(R9)CH2C(O)N(R9)R10;
R7 is XCH2C(R13)HpC(R13)H2 or XC(C(R13)HpC(R13)H2)2H where:
p is 0 to 5;
X is O, S(O)n (where n is 0 to 2), or N(R9);

and each R13 is independently C(OR9)HmCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9, CH2nN(R9)R10, CH2nOC(O)R9, CH2nSC(O)R9, CH2nN(R9)C(O)R9, CH2nOC(O)OR11, CH2nN(R9)C(O)OR11, CH2nOC(O)N(R9)R10, or CH2nN(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);
or R7 is selected from the group consisting of the following formulae:

28
where
q is 0 to 4;
p is 0 to 5;
each R13 is independently C(OR9)HmCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9, CH2nN(R9)R10, (CH2)nOC(O)R9, CH2nSC(O)R9, CH2nN(R9)C(O)R9, CH2nOC(O)OR11, CH2nN(R9)C(O)OR11, CH2nOC(O)N(R9)R10, or CH2nN(R9)C(O)N(R9)R10 (where each n is independently 0 to 2); and
each R14 is XCH2r or XCH2C(R13)Hr, where:
each r is independently 0 to 5, and
each X is O, S(O)n (where n is 0 to 2), or N(R9); and

each R13 is independently CH(OR9)mCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9, CH2nN(R9)R10, CH2nOC(O)R9, CH2nSC(O)R9, CH2nN(R9)C(O)R9, CH2nOC(O)OR11, CH2nN(R9)C(O)OR11, CH2nOC(O)N(R9)R10, or CH2nN(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);
each R9 and R10 is independently hydrogen, alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl);
each R11 is alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl); and
each R12 is independently an alkylene or alkylidene chain;
as a single stereoisomer or a mixture thereof; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
17. A method of treating a human having a disease-state characterized by thrombotic activity, which method comprises administering to a human in need thereof a therapeutically effective amount of a compound selected from the group consisting of the following formulae:

29
wherein:
A is C(R8) or N (where R8 is hydrogen, alkyl or halo);
Z1 is O, N(R9), CH2O or S(O)n (where n is 0 to 2);
Z2 is O, N(R9), OCH2 or S(O)n (where n is 0 to 2);
R1 and R4 are each independently hydrogen, halo, alkyl, nitro, OR9, C(O)OR9, C(O)N(R9)R10, N(R9)R10, N(R9)C(O)R9, or N(H)S(O)2R11;
R2 is C(NH)NH2, C(NH)N(H)OR9, C(NH)N(H)C(O)OR11, C(NH)N(H)C(O)R9, C(NH)N(H)S(O)2R11, or C(NH)N(H)C(O)N(H)R9;
R3 is hydrogen, halo, alkyl, haloalkyl, nitro, ureido, guanidino, OR9, C(NH)NH2, C(NH)N(H)OR9, C(O)N(R9)R10, R12C(O)N(R9)R10, CH(OH)C(O)N(R9)R10, N(R9)R10, R12N(R9)R10, C(O)OR9, R12C(O)OR9, N(R9)C(O)R9, (1,2)-tetrahydropyrimidinyl (optionally substituted by alkyl), (1,2)-imidazolyl (optionally substituted by alkyl), or (1,2)-imidazolinyl (optionally substituted by alkyl);
R5 and R6 are independently hydrogen, halo, alkyl, haloalkyl, nitro, N(R9)R10, C(O)OR9, C(O)N(R9)R10, C(O)N(R9)CH2C(O)N(R9)R10, N(R9)C(O)N(R9)R10, N(R9)C(O)R10, N(R9)S(O)2R11, or N(R9)C(O)N(R9)CH2C(O)N(R9)R10;
R7 is XCH2C(R13)HpC(R13)H2 or XC(C(R13)HpC(R13)H2)2H where:
p is 0 to 5;
X is O, S(O)n (where n is 0 to 2), or N(R9);
and each R13 is independently C(OR9)HmCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9, CH2nN(R9)R10, CH2nOC(O)R9, CH2nSC(O)R9, CH2nN(R9)C(O)R9, CH2nOC(O)OR11, CH2nN(R9)C(O)OR11, CH2nOC(O)N(R9)R10, or CH2nN(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);

or R7 is selected from the group consisting of the following formulae:

30
where
q is 0 to 4;
p is 0 to 5;
each R13 is independently C(OR9)HmCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9, CH2nN(R9)R10, (CH2)nOC(O)R9, CH2nSC(O)R9, CH2nN(R9)C(O)R9, CH2nOC(O)OR11, CH2nN(R9)C(O)OR11, CH2nOC(O)N(R9)R10, or CH2nN(R9)C(O)N(R9)R10 (where each n is independently 0 to 2); and
each R14 is XCH2r or XCH2C(R13)Hr where:
each r is independently 0 to 5, and
each X is O, S(O)n (where n is 0 to 2), or N(R9); and
each R13 is independently CH(OR9)mCH2OR9 (where m is 1 to 4), CH2nOR9, CH2nSR9, CH2nN(R9)R10, CH2nOC(O)R9, CH2nSC(O)R9, CH2nN(R9)C(O)R9, CH2nOC(O)OR11, CH2nN(R9)C(O)OR11, CH2nOC(O)N(R9)R10, or CH2nN(R9)C(O)N(R9)R10 (where each n is independently 0 to 2);

each R9 and R10 is independently hydrogen, alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl);
each R11 is alkyl, aryl (optionally substituted by halo, alkyl, hydroxy, alkoxy, aralkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl), or aralkyl (optionally substituted by halo, alkyl, aryl, hydroxy, alkoxy, aralkyl, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl); and
each R12 is independently an alkylene or alkylidene chain;
as a single stereoisomer or a mixture thereof; or a pharmaceutically acceptable salt thereof.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A device for use for forming an aperture in structure formed from unsolidified material that is capable of solidifying to a hard state, comprising:
a strand of flexible material that is helically coiled in the form of a preformed elongated member having adjacent coils between opposite ends of said preformed member removably bonded together and having a given outside diameter such that said preformed member may be embedded in unsolidified material with one of said ends extending at least close to a surface of said material such that when said material solidifies, said one end of said strand may be pulled to break the bonds between adjacent coils of said strand to remove said strand from said solidified material to form an aperture in said solidified material from the surface.
2. The device of claim 1, wherein:
said strand is formed of flexible plastic material helically coiled to form said preformed member.
3. The device of claim 1, wherein:
said preformed member has an aperture extending from said one end through the other of said ends with a cap coupled to said one end of said strand partially covering said aperture at said one end.
4. The device of claim 3, comprising:
gripping means coupled to said cap to facilitate removal of said preformed member from said solidified material.
5. The device of claim 3, wherein:
said strand is formed of flexible plastic material helically coiled to form said preformed member.
6. The device of claim 4, wherein:
said strand is formed of flexible plastic material helically coiled to form said preformed member.
7. The device of claim 1, wherein:
said strand is helically coiled to form said preformed member with an aperture extending from said one end to the other of said ends with said aperture at said other end being closed.
8. A method of forming an aperture into structure formed from unsolidified material that is capable of solidifying to a hard state comprising the steps of:
embedding an elongated preformed member having two opposite ends, in said unsolidified material with one of said ends located close to a surface of said material,
said preformed member comprises a strand of flexible material that is helically coiled and has adjacent coils which are removably bonded together and having a given outside diameter,
after said material solidifies, pulling said one end of said strand to separate the bonds between adjacent coils of said strand to remove said strand from said solidified material to form an aperture in said solidified material from said surface.
9. The method of claim 8, wherein:
said preformed member is embedded in said material when in an unsolidified state by pushing the other of said ends of said preformed member into said unsolidified material until said one end of said preformed member is located close to said surface of said material.
10. The method of claim 8, wherein:
said preformed member is embedded in said material when in an unsolidified state by attaching said preformed member to a support member, and
placing said unsolidified material around said preformed member with said one end located close to said surface of said material.
11. The method of claim 8, wherein:
said material of said structure comprises concrete.